Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. May 27, 2014; 6(5): 326-339
Published online May 27, 2014. doi: 10.4254/wjh.v6.i5.326
Published online May 27, 2014. doi: 10.4254/wjh.v6.i5.326
NS3 protease inhibitors for treatment of chronic hepatitis C: Efficacy and safety
Igor Bakulin, Anna Varlamicheva, Central Scientific Research Institute of Gastroenterology of Moscow Clinical Scientific Center, 111123 Moscow, Russia
Victor Pasechnikov, Irina Sannikova, Stavropol State Medical University, 355020 Stavropol, Russia
Author contributions: Bakulin I, Pasechnikov V, Varlamicheva A and Sannikova I analyzed publications and results of clinical trials; Varlamicheva A and Sannikova I wrote the manuscript; Bakulin I and Pasechnikov V corrected the manuscript and modified the language.
Correspondence to: Igor Bakulin, MD, PhD, Chief of the Department of Hepatology, Central Scientific Research Institute of Gastroenterology of Moscow Clinical Scientific Center, 86, Entuziastov highway, 111123 Moscow, Russia. passetchnikov@mail.ru
Telephone: +7-925-5186538 Fax: +7-499-3720023
Received: November 2, 2013
Revised: February 8, 2014
Accepted: April 11, 2014
Published online: May 27, 2014
Processing time: 207 Days and 8.5 Hours
Revised: February 8, 2014
Accepted: April 11, 2014
Published online: May 27, 2014
Processing time: 207 Days and 8.5 Hours
Core Tip
Core tip: This article reviews NS3/4A protease inhibitors, focusing on major criteria such as effectiveness and safety. Specific attention is paid to dosing regimens and adverse event profiles of protease inhibitor administered in clinical settings.